Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary Disease
Authors: Gerard M. Turino
Journal: Annals of Internal Medicine (2005)

Editorials6 September 2005Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary DiseaseGerard M. Turino, MDGerard M. Turino, MDFrom St. Luke's-Roosevelt Hospital, Columbia University College of Physicians & Surgeons, New York, NY.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-5-200509060-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Chronic obstructive pulmonary disease (COPD) is a major global medical problem. In the United States, COPD causes more than 500 000 hospitalizations and 100 000 deaths per year (1, 2). As many as 25 million individuals are estimated to have various stages of COPD in the United States (3). The definition of COPD, which resulted from a National Heart, Lung, and Blood Institute and World Health Organization conference, is "a disease state characterized by airflow obstruction that is not fully reversible. The airflow obstruction is usually both progressive and associated with an abnormal inflammatory response of the lung to noxious particles or ...References1. Owings MF, Lawrence L. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1997. Vital Health Stat 13. 1999;:1-157. [PMID: 10665293] MedlineGoogle Scholar2. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep. 2001;49:1-113. [PMID: 11591077] MedlineGoogle Scholar3. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. MMWR Surveill Summ. 2002;51:1-16. [PMID: 12198919] MedlineGoogle Scholar4. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76. [PMID: 11316667] CrossrefMedlineGoogle Scholar5. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005-12. [PMID: 14999112] CrossrefMedlineGoogle Scholar6. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204. [PMID: 3492164] LinkGoogle Scholar7. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-22. [PMID: 9603117] CrossrefMedlineGoogle Scholar8. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117:5S-9S. [PMID: 10673466] CrossrefMedlineGoogle Scholar9. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med. 2005;143:317-26. LinkGoogle Scholar10. Disse B, Witek TJ. Anticholinergics: tiotropium.. In: Hansel TT, Barnes PJ, eds. Progress in Respiratory Research. New Drugs for Asthma, Allergy and COPD. Vol 31. Basel, Switzerland: Karger; 2001:72-6. Google Scholar11. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995;8:1506-13. [PMID: 8575576] MedlineGoogle Scholar12. Calverly PM, Towse LJ, Lee A. The timing of dose and pattern of bronchodilation of tiotropium (TIO) in stable COPD. Eur Respir J. 2000;16:56S. MedlineGoogle Scholar13. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;:CD002876. [PMID: 15846642] MedlineGoogle Scholar14. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-8. [PMID: 14605043] CrossrefMedlineGoogle Scholar15. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-24. [PMID: 11866001] CrossrefMedlineGoogle Scholar16. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-16. [PMID: 11871363] CrossrefMedlineGoogle Scholar17. Waters CM, Sporn PH, Liu M, Fredberg JJ. Cellular biomechanics in the lung. Am J Physiol Lung Cell Mol Physiol. 2002;283:L503-9. [PMID: 12169567] CrossrefMedlineGoogle Scholar18. Milic-Emili J. Does mechanical injury of the peripheral airways play a role in the genesis of COPD in smokers? COPD. 2004;1:85-92. CrossrefMedlineGoogle Scholar19. Ricard JD, Dreyfuss D, Saumon G. Production of inflammatory cytokines in ventilator-induced lung injury: a reappraisal. Am J Respir Crit Care Med. 2001;163:1176-80. [PMID: 11316656] CrossrefMedlineGoogle Scholar20. Vlahakis NE, Schroeder MA, Limper AH, Hubmayr RD. Stretch induces cytokine release by alveolar epithelial cells in vitro. Am J Physiol. 1999;277:L167-73. [PMID: 10409244] MedlineGoogle Scholar21. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, et al. The burden of obstructive lung disease initiative (BOLD): rationale and design. Journal of Chronic Obstructive Pulmonary Disease. 2005;2:277-83. CrossrefGoogle Scholar22. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther. 2005;18:75-81. [PMID: 15649848] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Gerard M. Turino, MDAffiliations: From St. Luke's-Roosevelt Hospital, Columbia University College of Physicians & Surgeons, New York, NY.Disclosures: Grants received (Boehringer Ingelheim); Grants pending (Boehringer Ingelheim).Corresponding Author: Gerard M. Turino, MD, St. Luke's-Roosevelt Hospital, 1000 10th Avenue, New York, NY 10019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPrevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator Dennis E. Niewoehner , Kathryn Rice , Claudia Cote , Daniel Paulson , J. Allen D. Cooper Jr. , Larry Korducki , Cara Cassino , and Steven Kesten Metrics Cited byChronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic BronchodilationCurrent World LiteratureThe effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease 6 September 2005Volume 143, Issue 5Page: 386-387KeywordsBronchodilatorsChronic obstructive pulmonary diseaseDyspneaHealth careHospitalizationsLungsQuality of lifeResearch designRespiratory system procedures ePublished: 6 September 2005 Issue Published: 6 September 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...